Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LMY-920 for Relapsed/Refractory CLL/SLL
NCT06916767Phase 1Recruiting
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of BAFF CAR-T in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jul 2025; status: recruiting.
02
Drugs
BAFF CAR-T
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06916767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06916767.